Orbelli

Complete Ingredient Profile

Ingredient Name & Common Synonyms

Primary Name: D-chiro-inositol
Common Synonyms: DCI, D-Chiro-Inositol, (1R,2R,3S,4R,5S,6R)-Cyclohexane-1,2,3,4,5,6-hexol, Pinitol derivative
Chemical Classification: Cyclic polyol, Inositol stereoisomer, Insulin second messenger
Molecular Formula: C₆H₁₂O₆

Overview

Botanical Family: Naturally occurring in legumes (Fabaceae), buckwheat, and carob
Primary Origin: Pinitol from carob pods (Ceratonia siliqua), legumes, buckwheat
Extraction Method: Enzymatic conversion from myo-inositol or extraction from plant sources
Molecular Structure: Stereoisomer of myo-inositol with different hydroxyl group orientations
Appearance: White, crystalline powder, odorless with a slightly sweet taste

Benefits & Uses

For Women's Hormonal Health:

Optimal PCOS Therapy: The 40:1 MI/DCI ratio is the best for PCOS therapy aimed at restoring ovulation and normalizing important parameters in these patients
Hormonal & Metabolic Improvements: Supplementation improved the metabolic and hormonal profile in PCOS phenotype A patients
Evidence-Based Ratios: The MYO/DCI combination is effective when used at a ratio of at least 40:1
Physiological Balance: Inositol isomers have a physiological ratio of 40:1 in most healthy tissues

Your Perfect Formula Ratio:

Orbelli's Ratio: 2000mg Myo-inositol: 50mg D-chiro-inositol = 40:1 ratio
Scientifically Validated: Matches the exact ratio proven most effective in clinical studies
Optimal Synergy: The best MI:DCI ratio is 40:1 for PCOS treatment

Mechanism of Action:

Insulin Signaling: Different pathway from myo-inositol, both are essential for complete insulin function
Ovarian Function: Specifically supports ovarian insulin sensitivity and steroidogenesis
Glucose Metabolism: Enhances peripheral glucose uptake through distinct mechanisms
Hormonal Balance: Helps normalize androgen levels and improve menstrual regularity

Safety & Warnings

General Safety Profile:

None of the participants reported side effects in clinical combination studies, and inositol is well tolerated in the recommended dose with no clinically relevant adverse effects

Dosage Safety:

Safe Range: 25-500mg daily in clinical studies when used in proper ratios
Orbelli Dosage: 50mg per serving - optimal dose for 40:1 ratio with myo-inositol
Critical Warning: Long-term treatments with high dosages of D-chiro-inositol can predispose women to hormonal and menstrual abnormalities
Your Advantage: Conservative 50mg dose avoids high-dose complications

Potential Side Effects:

Minimal at Correct Ratios: Side effects typically occur at high doses (more than three times the recommended dose)
Combination Safety: Most individuals experience only mild side effects, which can include nausea, gas, and difficulty sleeping
Ratio-Dependent: High D-Chiro-ins concentrations can significantly reduce myo-Ins bioavailability

Important Warnings:

Ratio Critical: Never take D-chiro-inositol alone - must be combined with myo-inositol in a 40:1 ratio
High Dose Risk: Avoid high doses alone - can cause hormonal imbalances
May cause mild throat irritation in some individuals - this is normal and typically resolves quickly
Blood Sugar Effects: May interact with insulin or other glucose-lowering medications due to its potential to affect insulin sensitivity

Recommended Patch-Test Instructions:

Not applicable for oral supplements. For topical applications containing D-chiro-inositol, perform a 48-hour patch test on the inner forearm.

Formulation Tips

Physical Properties:

pH Range: 6.0-8.0 (slightly alkaline in aqueous solution)
Solubility: Highly soluble in water (8g/100mL at 25°C), slightly soluble in alcohol
Stability: Heat-stable up to 180°C, stable across the pH range 4-9
Critical Ratio: Must maintain an exact 40:1 ratio with myo-inositol

Optimal Dosing:

Therapeutic Range: 25-100mg daily when properly combined with myo-inositol
Orbelli Formula: 50mg per serving - perfect for a 40:1 ratio with 2000mg myo-inositol
Bioavailability: Good oral absorption, works synergistically with myo-inositol
Timing: Take together with myo-inositol for optimal efficacy

Pairing Suggestions:

Essential Pairing: MUST be combined with myo-inositol in a 40:1 ratio
Synergistic with: Alpha-lipoic acid, folic acid, chromium, other insulin sensitizers
Enhanced by: Taking with a complete amino acid profile for reproductive support
Best taken: With myo-inositol, consistent timing, with or without food

Critical Formulation Notes:

Ratio Maintenance: Any deviation from a 40:1 ratio reduces effectiveness
Quality Control: Ensure precise measurements for consistent ratios
Stability Testing: Monitor ratio stability throughout shelf life

Scientific References

Latest Clinical Study (2024): The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with PCOS - PubMed, 2024
Comprehensive Review (2023): Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome - Climacteric, 2023
Ovulation Restoration Study: The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients - European Review, 2019
Animal Model Validation: Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model - PubMed, 2018
Competitive Inhibition Study: PCOS and Inositols: Basic Differences Between D-Chiro and Myo-Inositol - Frontiers in Endocrinology, 2021
Safety Assessment: The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes - PubMed, 2016
High-Dose Warning Study: Long-Lasting Therapies with High Doses of D-chiro-inositol: The Downside - PMC, 2023
Metabolomic Study: Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in PCOS patients - Journal of Ovarian Research, 2019

Related Orbelli Products

Women's Hormonal Balance - Features 50mg D-chiro-inositol in a perfect 40:1 ratio with 2000mg Myo-inositol
Scientifically validated combination for optimal PCOS and hormonal support
Additional product links to be added

Last updated: August 2025 | This information is for educational purposes only and not intended as medical advice.